DPPA-3: Potential Drug Target for Alzheimer's? (G359787)

Target Name: DPPA3

NCBI ID: G359787

DPPA3

DPPA-3: Potential Drug Target for Alzheimer's?

DPPA-3 (doublecortin-related protein 3) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is characterized by its unique structure, which consists of a long extracellular domain, a short transmembrane segment, and a short intracellular tail.

One of the unique features of DPPA-3 is its ability to interact with other proteins, particularly doublecortin, a protein that is also known as calbindin. This interaction between DPPA-3 and doublecortin has led to the speculation that DPPA-3 may be a drug target or biomarker for the disease Alzheimer's disease.

DPPA-3 has been shown to play a role in the development and progression of Alzheimer's disease. Studies have shown thatDPPA-3 levels are reduced in the brains of individuals with Alzheimer's disease compared to age-matched control individuals. Additionally, overexpression ofDPPA-3 has been shown to increase the expression ofdoublecortin in rat brains, a protein that is known to contribute to the development of Alzheimer's disease.

DPPA-3 has also been shown to interact with other proteins that are involved in the development and progression of Alzheimer's disease. For example, studies have shown thatDPPA-3 interacts with the protein TREBP, which is involved in the production of amyloid peptides. Additionally,DPPA-3 has been shown to interact with the protein BACE1, which is involved in the production of beta-amyloid peptides.

The potential drug target for DPPA-3 is related to its ability to interact with doublecortin and other proteins that are involved in the development and progression of Alzheimer's disease.DPPA-3 has been shown to be a good candidate for a drug that targets the production of beta-amyloid peptides, which are a hallmark of Alzheimer's disease.

In conclusion, DPPA-3 is a protein that has been shown to play a role in the development and progression of Alzheimer's disease. Its unique structure, which consists of a long extracellular domain, a short transmembrane segment, and a short intracellular tail, as well as its ability to interact with other proteins, particularly doublecortin, makes it a promising candidate for a drug target or biomarker for Alzheimer's disease. Further research is needed to fully understand the role of DPPA-3 in the development and progression of Alzheimer's disease.

Protein Name: Developmental Pluripotency Associated 3

Functions: Primordial germ cell (PGCs)-specific protein involved in epigenetic chromatin reprogramming in the zygote following fertilization (PubMed:35314832). In zygotes, DNA demethylation occurs selectively in the paternal pronucleus before the first cell division, while the adjacent maternal pronucleus and certain paternally-imprinted loci are protected from this process (By similarity). Participates in protection of DNA methylation in the maternal pronucleus by preventing conversion of 5mC to 5hmC: specifically recognizes and binds histone H3 dimethylated at 'Lys-9' (H3K9me2) on maternal genome, and protects maternal genome from TET3-mediated conversion to 5hmC and subsequent DNA demethylation (By similarity). Does not bind paternal chromatin, which is mainly packed into protamine and does not contain much H3K9me2 mark (By similarity). Also protects imprinted loci that are marked with H3K9me2 in mature sperm from DNA demethylation in early embryogenesis (By similarity). May be important for the totipotent/pluripotent states continuing through preimplantation development (By similarity). Also involved in chromatin condensation in oocytogenesis (By similarity)

The "DPPA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DPPA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets